Enhancing HER2 testing in breast cancer: predicting fluorescence in situ hybridization (FISH) scores from immunohistochemistry images via deep learning
Abstract Breast cancer affects millions globally, necessitating precise biomarker testing for effective treatment. HER2 testing is crucial for guiding therapy, particularly with novel antibody‐drug conjugates (ADCs) like trastuzumab deruxtecan, which shows promise for breast cancers with low HER2 ex...
Saved in:
| Main Authors: | Daniel O Macaulay, Wenchao Han, Mark D Zarella, Chris A Garcia, Thomas E Tavolara |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | The Journal of Pathology: Clinical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/2056-4538.70024 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization
by: Jingmin Zhong, et al.
Published: (2025-01-01) -
Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
by: Agata Wróbel, et al.
Published: (2025-04-01) -
Interobserver variability in her2 immunohistochemistry analysis and its clinical implications with the advent of the HER2-low category
by: Ana Catharina Joaquim, et al.
Published: (2025-08-01) -
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine
by: Sila Oksuz, et al.
Published: (2025-04-01) -
FICTION Technique—A Candidate for the Assessment of HER2 Status in Breast Invasive Carcinomas
by: Bogdan Fetica, et al.
Published: (2025-06-01)